Matinas BioPharma Holdings (MTNB) EBT Growth (3y) (2017 - 2026)
Matinas BioPharma Holdings (MTNB) EBT Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.22% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 12.16% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 103.69% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 24.03% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 41.79% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 38.36% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -27.69% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 64.03% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -38.56% |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - | 36.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.80% |
| Mar 31, 2026 | 33.68% |
| Dec 31, 2025 | 64.98% |
| Sep 30, 2025 | 44.72% |
| Jun 30, 2025 | 43.05% |
| Mar 31, 2025 | 38.57% |
| Dec 31, 2024 | 39.16% |
| Sep 30, 2024 | 25.78% |
| Jun 30, 2024 | -20.90% |
| Mar 31, 2024 | 3.00% |
| Dec 31, 2023 | 42.94% |
| Sep 30, 2023 | -8.57% |
| Jun 30, 2023 | -7.68% |
| Mar 31, 2023 | -1.63% |
| Dec 31, 2022 | -16.16% |
| Sep 30, 2022 | -20.86% |
| Jun 30, 2022 | -23.79% |
| Mar 31, 2022 | 6.35% |
| Dec 31, 2021 | -108.32% |
| Sep 30, 2021 | -43.00% |